Table 3.
High baseline KL-6 predicts progression of ILD based on the course of the FVC and DLCO over 1 year in patients randomized to CYC and MMF.
Variable | Estimate | 95% CI | P-Value | |
---|---|---|---|---|
Outcome: Course of FVC over 12 months in CYC arm | ||||
Intercept | 9.99 | 7.02 | 12.26 | 0.001 |
KL-6 | −0.32 | −0.50 | −0.11 | 0.024 |
Baseline FVC | 0.88 | 0.87 | 0.90 | <0.001 |
Time | 0.10 | 0.028 | 0.17 | 0.004 |
Outcome: Course of FVC over 12 months in MMF arm | ||||
Intercept | 16.92 | 12.12 | 21.99 | <0.001 |
KL-6 | −0.72 | −1.03 | −0.32 | 0.005 |
Baseline FVC | 0.85 | 0.80 | 0.89 | <0.001 |
Time | 0.054 | −0.015 | 0.12 | 0.128 |
Outcome: Course of DLCO over 12 months in CYC arm | ||||
Intercept | 18.11 | 14.63 | 20.60 | <0.001 |
KL-6 | −1.30 | −1.51 | −1.00 | <0.001 |
Baseline DLCO | 0.85 | 0.84 | 0.87 | <0.001 |
Time | −0.024 | −0.12 | 0.076 | 0.634 |
Outcome: Course of DLCO over 12 months in MMF arm | ||||
Intercept | 23.80 | 17.42 | 26.21 | 0.001 |
KL-6 | −1.28 | −1.46 | −0.84 | 0.004 |
Baseline DLCO | 0.80 | 0.78 | 0.84 | <0.001 |
Time | 0.030 | −0.051 | 0.11 | 0.428 |